Home Stocks ViiV HIV PrEP therapy outperforms Gilead’s lenacapavir (PFE)
Stocks

ViiV HIV PrEP therapy outperforms Gilead’s lenacapavir (PFE)

by Deidre Salcido
written by Deidre Salcido 0 comments
Image 1772605439.jpg

Pixelimage

ViiV Healthcare, a healthcare company founded by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), announced on Wednesday that its long-acting HIV PrEP therapy cabotegravir was found to be more acceptable to patients compared to Gilead Sciences’ (NASDAQ:

Deidre Salcido

You may also like

The cheapest ticket to see Team USA play in the FIFA World Cup...

Stellantis shares jolted higher by $13B investment in U.S. manufacturing (STLA:NYSE)

AMD is keeping its momentum alive. Here are two reasons for optimism.

Japanese payment app PayPay valuation to likely exceed $20B in U.S. IPO –...

Is there such a thing as too much Taylor Swift? Not for Disney.

Oakmark Global Fund adds Salesforce, exits Amazon.com in Q3

Leave a Comment

Save my name, email, and website in this browser for the next time I comment.

About Us

Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.

Facebook Twitter Youtube Linkedin Instagram

Garry Marr: Why micro condos will survive the current downturn, even if they've lost their allure for now

Recent Articles

CMB International tokenizes its $3.8B money market fund on BNB Chain
The Block 2025 Episode 48 recap: Han and Can’s landscaper cops a spray from site managers
10 exceptionally promising Valencia-based startups to watch in 2025 and beyond

Featured

Garry Marr: Why micro condos will survive the current downturn, even if they've lost their allure for now
CMB International tokenizes its $3.8B money market fund on BNB Chain
The Block 2025 Episode 48 recap: Han and Can’s landscaper cops a spray from site managers

© 2025 AI Investor Picks – All Rights Reserved

AI Investor Picks
© 2025 AI Investor Picks - All Rights Reserved
Close